Comparison of Ranibizumab Monotherapy and Ranibizumab Combination Therapies in Recurrent or Persistent Choroidal Neovascularization Secondary to Age-related Macular Degeneration

NCT01162746 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Age-Related Macular Degeneration
Neovascularization, Choroidal

Interventions

DRUG: Intravitreal dexamethasone and intravitreal ranibizumab
DRUG: Intravitreal ranibizumab

Sponsor

Medical University of Vienna